» Articles » PMID: 17325894

Renal Failure in Multiple Myeloma: Incidence, Correlations, and Prognostic Significance

Overview
Journal Leuk Lymphoma
Specialties Hematology
Oncology
Date 2007 Feb 28
PMID 17325894
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Renal failure (RF) is a common and severe complication of patients with multiple myeloma (MM). The purpose of our study was to assess the incidence of RF in a contemporary series of newly diagnosed patients with MM, its association with specific clinical and laboratory features, and its impact on patients' outcome. Over the last decade, 756 newly diagnosed symptomatic patients with MM were included in our database. Renal failure, defined as a serum creatinine >or= 2 mg/dl at the time of diagnosis, was seen in 21% of patients. Multiple parameters were associated with RF, but logistic regression analysis showed that RF was independently associated only with International Staging System and Bence Jones proteinuria. The presence of RF was associated with a trend for higher early death rate but with a similar response to primary therapy. The median survival of patients with RF was 19.5 months versus 40.4 months for patients without RF (p < 0.001). Several variables were associated with impaired survival by univariate analysis. When multivariate analysis was performed the independent variables were poor performance status, thrombocytopenia, advanced age, high LDH and elevated serum beta2 microglobulin but not high creatinine. When corrected for stage, renal failure had no impact on survival.

Citing Articles

Bibliometric and Bioinformatics Analysis of Renal Impairment in Multiple Myeloma: Trends and Research Hotspots, and Associated Genetic Pathways (2000-2023).

Jiang H, Bai X J Multidiscip Healthc. 2025; 18:1147-1162.

PMID: 40026868 PMC: 11872101. DOI: 10.2147/JMDH.S501551.


Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group.

Waszczuk-Gajda A, Vesole D, Malyszko J, Jurczyszyn A, Wrobel T, Drozd-Sokolowska J Arch Med Sci. 2025; 20(6):1864-1873.

PMID: 39967949 PMC: 11831329. DOI: 10.5114/aoms.2020.93442.


Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis.

Bai H, Zhang C, Zhao A, Tang W, Zhang L Ther Adv Hematol. 2025; 16:20406207251319593.

PMID: 39963097 PMC: 11831653. DOI: 10.1177/20406207251319593.


Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma.

Utsu Y, Isono Y, Masuda S, Arai H, Shimoji S, Matsumoto R Ann Hematol. 2025; 104(1):573-579.

PMID: 39870910 PMC: 11868295. DOI: 10.1007/s00277-025-06201-8.


Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients.

Carvalho L, Assis R, Montenegro C, da Rosa M, Pereira M, Pitta M Int J Mol Sci. 2025; 25(24.

PMID: 39769262 PMC: 11676459. DOI: 10.3390/ijms252413499.